RTTNews | Oct 14, 2020 02:46AM EDT

02:46 Wednesday, October 14, 2020 (RTTNews.com) - Nestle SA (NSRGY.PK, NSTR.L) announced the completion of its acquisition of Aimmune Therapeutics, Inc. (AIMT). Andrew Oxtoby has been named as Aimmune's President & CEO. He was previously Aimmune's Chief Commercial Officer.

The tender offer for all of the outstanding shares of Aimmune common stock, other than shares held by Nestl and its affiliates, for a price of $34.50 per share in cash expired on October 9, 2020. The minimum tender condition and all of the other conditions to the offer were satisfied and on October 13. Nestl through a subsidiary, accepted for payment all shares validly tendered and not properly withdrawn. Aimmune stock has ceased to be traded on the NASDAQ Global Market.

Read the original article on RTTNews ( https://www.rttnews.com/3135992/nestle-completes-acquisition-of-aimmune-therapeutics-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved